Sunday, July 18, 2021
Home Breaking News GBT Continues Research on AI Detection System

GBT Continues Research on AI Detection System

SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) — GBT Technologies Inc. (OTC PINK: GTCH) (“GBT”, or the “Company”), announced that its joint venture, GBT Tokenize Corp. (“GBT/Tokenize”), is continuing with its research associated with an AI system to detect and open clogs within arteries based on its proprietary radio technology, which has an internal code name of “Hermes”.

The research is evaluating a system targeted for arterial clogs cleaning, such as a coronary artery, peripheral artery, or any other body vascular organ. The researching is focusing on the use of an intravenous mini-probe unit that could travel within the artery, searching to find clogs including complete blockages (Total Occlusions). Upon detecting a clog, GBT/Tokenize will evaluate whether the system will have the capability to remove it and clear the blood vessel for efficient blood flow. This blockage may cause a condition called atherosclerosis (when a substance called plaque builds up in the walls of the arteries) and can eventually block the artery, causing vascular disease, heart attack or stroke. The research is evaluating whether the unit can use AI based and radio frequency imaging system to “see” within arteries. We are now researching the development of a low frequency radio system to scan within arteries, producing 3D visuals, shown on a computer screen, and used for intravenous navigation.

GBT/Tokenize is evaluating developing a system that will have the capability to be manually remote controlled by physicians or to autonomously operated inside blood vessels. It is intended that an advanced SOC (System on Chip) microchip with an embedded software will control the unit’s operations. The goal is to research the inclusion of a wireless communication capability to produce a computerized 3D imaging for the operating physician. We are evaluating initial setup of the system for inserted into a human body, for example through a large leg artery, and autonomously or manually travel further to other parts of the body. Using a variety of micro-sensors, we are researching the viability of a system that will search and remove clogs without damaging the vessel’s tissue. The device is intended to use an innovative AI controlled propulsion system that is based on water jet propulsion concept that does not involve external, rotating moving parts to avoid artery’s walls damages. This research is looking into the viability of the use of the most recent micromachining mechanical engineering technology.

“Our AI technology can be implemented in a wide variety of applications to control mechanical, optical and electrical systems, analyzing arterial data and making decisions in real time. We are commencing research – code name Hermes, to use our AI capabilities to search, identify and remove plaque within arteries and blood vessels. In this project, we are researching the ability to use GBT Tokenize’s AI technology to control a mini-probe unit that will be inserted into a human body through a main artery. If our research is positively concluded, we believe that this type of system can be a breakthrough within the cardiovascular domain, offering less invasive treatments and introducing a new method to save lives. Artificial Intelligence technology encapsulates the future health care and we’re investing vast efforts to utilize our experience and knowledge in this domain.”

If the research of the device is successfully concluded, the Company will be required to obtain approval for use of the device from the US Food and Drug Administration (“FDA”). Further, following the conclusion of the research, the development of this product would require significant funds as well as the partnering with a company that specializes in the development of medical devices and obtaining FDA approval.

About Us

GBT Technologies, Inc. (OTC PINK: GTCH) (“GBT”) ( http://gbtti.com ) is a development stage company which considers itself a native of Internet of Things (IoT), Artificial Intelligence (AI) and Enabled Mobile Technology Platforms used to increase IC performance. GBT has assembled a team with extensive technology expertise and is building an intellectual property portfolio consisting of many patents. GBT’s mission, to license the technology and IP to synergetic partners in the areas of hardware and software. Once commercialized, it is GBT’s goal to have a suite of products including smart microchips, AI, encryption, Blockchain, IC design, mobile security applications, database management protocols, with tracking and supporting cloud software (without the need for GPS). GBT envisions this system as a creation of a global mesh network using advanced nodes and super performing new generation IC technology. The core of the system will be its advanced microchip technology; technology that can be installed in any mobile or fixed device worldwide. GBT’s vision is to produce this system as a low cost, secure, private-mesh-network between any and all enabled devices. Thus, providing shared processing, advanced mobile database management and sharing while using these enhanced mobile features as an alternative to traditional carrier services.


Forward-Looking Statements

Certain statements contained in this press release may constitute “forward-looking statements”. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( http://www.sec.gov ). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of the press release.

Contact:
Dr. Danny Rittman, CTO
press@gopherprotocol.com


Disclaimer

This article is for the purposes of solicitation subscriptions for this website. This website expects to generate new advertisement revenue resulting from the distribution of this article. The amount of which is unknown at this time. This website or it’s authors do not own any shares of GBT Technologies Inc (GTCH) and does not buy, sell, or trade any shares of (GTCH). This article does not provide a professional analysis of a (GTCH) financial position. (GTCH) financial position and all other information regarding the featured Company should be verified directly with (GTCH). Please read our full disclaimer for more detailed information.

Most Popular

NxGen Brands, Inc. Enters Into A Definitive Agreement To Acquire 100% Of Healthcard LLC; Acquisition Brings Company Ownership Of Proprietary Patent Pending Patient Centric...

NxGen Brands, Inc. Enters Into A Definitive Agreement To Acquire 100% Of Healthcard LLC; Acquisition Brings Company Ownership Of Proprietary Patent Pending Patient...

NxGen Brands, Signs Letter of Intent (LOI) to Acquire HealthCard, Technology Company That Has Patent Pending Registration for Patient Centric Universal Health Recording &...

NxGen Brands, Signs Letter of Intent (LOI) to Acquire HealthCard, Technology Company That Has Patent Pending Registration for Patient Centric Universal Health Recording...

Nutra Pharma Announces that Diverse Health Services has Added Nyloxin to Their Product Offerings

Diverse Health Services, an industry leader in Chiropractic care and Alternative Medicine, announced the addition of the Nyloxin(R) line of pain relief...

Nutra Pharma Announces Private Label Expansion of their Over-The-Counter Pain Relievers

Nutra Pharma is announcing the first private label agreement in expansion of their line of over-the-counter pain relievers and anti-inflammatory drugs

ADVERTISEMENT

Subscribe to our Stock News Alerts

Mobile is not required however if you want the fastest
delivery be sure to add your mobile.

Subscribe to our News Alerts